Peptide education
Palmitoyl Hexapeptide-12 (VGVAPG)
Pal-VGVAPG
This page covers the VGVAPG form of palmitoyl hexapeptide-12, a short peptide attached to a fatty acid and used in topical skin-care products. The VGVAPG sequence comes from elastin.
Researchers observed penetration and changes in water retention in separate excised human skin models. Those experiments do not show how much a finished cosmetic improves skin appearance or barrier function in living people.
Overview
Quick answer
The old ingredient name palmitoyl oligopeptide could describe more than one peptide. The cosmetic safety assessment covers the VGVAPG sequence, not the alternative hexapeptide-12 sequence described in its report.
What is it?
It is a six-amino-acid peptide linked to palmitic acid. The VGVAPG form is used in cosmetic skin-care formulations.
What did researchers measure?
Researchers detected the peptide in outer layers of one donor's excised skin. In a separate model using another donor's skin, lipid-depleted samples lost less water during laboratory drying.
Does that prove a visible result?
No. A laboratory skin sample cannot establish wrinkle improvement or barrier repair in people using a finished product.
What is known about safety?
A cosmetic ingredient panel reviewed the VGVAPG form and concluded it was safe under the uses and concentrations described in its assessment. A finished product can still irritate an individual person's skin.
Evidence
Evidence snapshot
Researchers tracked peptide distribution in one donor's skin and measured water retention in lipid-depleted skin from a different donor. This was not a clinical trial.
The safety panel's conclusion applies to VGVAPG in the cosmetic practices it evaluated, not every sequence or concentration bearing a similar name.
Penetration and water retention in a laboratory sample are different endpoints from visible skin changes in people.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| It repairs the skin barrier. | The delivery experiment used excised skin, not people applying a product. | Treated, lipid-depleted tissue lost less water during laboratory drying tests. | The result is a laboratory observation, not proof of clinical barrier repair. |
| Every product with this ingredient will visibly reduce wrinkles. | The skin experiment did not measure wrinkles in living participants. | A product's ingredients and delivery system need their own evidence for an appearance claim. |
Bottom line
Main takeaway
This is a skin-care ingredient, and the direct experiment used skin samples outside the body.
A shared ingredient name does not make different vehicles or concentrations equivalent.
Separate ex vivo delivery and barrier measurements from clinical efficacy and tolerability.
Identity
What it is
Pal-VGVAPG is an elastin-sequence hexapeptide with a palmitoyl group. It is used in topical cosmetic formulations.
Palmitoyl oligopeptide was a less specific ingredient name that could refer to either this peptide or palmitoyl tripeptide-1.
Use context
Routes, doses, and cycle patterns
In the skin-distribution experiment, researchers exposed excised skin to a 1% peptide solution for 8 hours. This experimental exposure is not a consumer product schedule and is much higher than the maximum reported leave-on use concentration in the safety assessment.
Human studies and product labels
Excised-skin distribution experiment
- Purpose
- Measure peptide distribution in skin
- Context
- Laboratory diffusion-cell experiment
- Route
- Applied to excised human skin
- Amount
- 100 microliters of 1% solution per square centimeter
- Frequency
- One experimental exposure
- Duration
- 8 hours
The method used full-thickness skin from one donor to test penetration, not a clinical skin-care regimen.
Research
Research evidence
The excised-skin study measured tissue behavior, not clinical outcomes. The safety assessment also considered human patch tests of cosmetic mixtures, which address irritation and sensitization rather than effectiveness.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Cosmetic ingredient safety assessment | Human patch-test participants and other test systems | Expert review of ingredient and mixture safety data | Cosmetic mixtures containing the assessed peptides | The panel concluded that the VGVAPG form was safe under the cosmetic practices and concentrations described in the assessment. | Patch tests do not establish wrinkle improvement or exclude every individual reaction. The conclusion does not cover the alternate hexapeptide sequence. | Cosmetic safety assessment |
Cautions
Safety and unknowns
- The safety panel's conclusion covers specified cosmetic uses and the VGVAPG sequence. It did not assess the alternative hexapeptide-12 sequence.
- The panel noted that published reproductive, developmental, and carcinogenicity data for the reviewed ingredients were not found. Its conclusion considered the available data and the low cosmetic concentrations reported to it.
- Irritation or sensitivity can arise from a finished formulation, even when an ingredient has a favorable cosmetic safety assessment.
Product quality
Product identity and quality
The full formulation, peptide sequence, and concentration matter when comparing products.
Ingredient identity
The retired name palmitoyl oligopeptide can refer to different peptides.
Formulation
A laboratory solution and a finished serum need not behave the same way on skin.
Mechanism
How it is proposed to work
The peptide can interact with skin components in laboratory models. Researchers have studied where it goes in excised skin and how it affects water retention.
In a diffusion-cell experiment using one donor's skin, researchers detected peptide signals through the outer skin and into the epidermis.
Lipid-depleted samples from another donor retained water better after peptide treatment in the measured drying conditions. Living skin and finished products may behave differently.
Details
Technical details
Sources
References
- 1.
doi:10.1021/acsabm.4c01816 PMID:39964201
Laboratory experiments using excised human skin and skin components. Penetration and drying experiments used skin from different single donors; this was not a clinical efficacy trial.
- 2.
Cosmetic Ingredient Review. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics
Final assessment for cosmetic use, including the VGVAPG sequence of palmitoyl hexapeptide-12.
- 3.
FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
US guidance on how a product's intended use affects its regulatory category.